echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 8 million 350 thousand yuan! Saisheng pharmaceutical won two monoclonal antibody technologies in research of green bamboo biology

    8 million 350 thousand yuan! Saisheng pharmaceutical won two monoclonal antibody technologies in research of green bamboo biology

    • Last Update: 2019-07-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On July 24, saisheng pharmaceutical announced that the company signed a technology transfer contract with Beijing green bamboo Biotechnology Co., Ltd (hereinafter referred to as "green bamboo biotechnology"), which stipulated that green bamboo biotechnology would transfer relevant technologies of "human monoclonal antibody K3 and K11" to saisheng pharmaceutical, with a total transfer fee of 8.35 million yuan "K3 monoclonal antibody", also known as anti-human tumor necrosis factor monoclonal antibody injection Anti human tumor necrosis factor monoclonal antibody injection is a biological analogue of adalimumab injection (trade name: sumilar, Humira); the primary structure of light chain and heavy chain of monoclonal antibody is completely consistent with adalimumab, and the quality standard of K3 monoclonal antibody injection is the same as that of adalimumab K3 McAb was expressed in chok1 cells The culture medium used was limited by chemical components, and it did not contain protein from animal and plant sources It is mainly used for the treatment of autoimmune diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis, ulcerative colitis and other diseases K11 mAb, also known as humanized anti VEGF mAb injection humanized anti VEGF mAb injection, is a biologically similar drug of bevacizumab (trade name: Avastin); the primary structure of light chain and heavy chain of mAb is completely consistent with bevacizumab, and the quality standard of K11 mAb injection is the same as that of bevacizumab K11 McAb was expressed in chok1 cells The culture medium used was limited by chemical components, and it did not contain protein from animal and plant sources K11 monoclonal antibody / bevacizumab is a monoclonal antibody combining with human vascular endothelial growth factor It can prevent the formation and growth of blood vessels after binding with VEGF, and make the blood supply in tumor tissue obstruct, resulting in the unsustainable growth of tumor When combined with cytotoxic synthetic drugs, it can significantly inhibit the growth of tumor, and significantly reduce the volume of existing malignant tumor It is mainly used for the junction Treatment of cancer such as rectal cancer and lung cancer The announcement shows that "human monoclonal antibody K3, K11" project has completed preclinical research according to the requirements of applying for national class II new drugs; it has passed the review of CDE of national drug administration, obtained the approval for clinical research, and carried out phase I clinical research Beijing saisheng Pharmaceutical Co., Ltd signed the technology transfer contract on the project of "human monoclonal antibody K3, K11" with green bamboo biology It is agreed in the contract that the transfer of green bamboo biology to Beijing saisheng Pharmaceutical Co., Ltd involves the test results and research data of pre clinical research of human monoclonal antibody K3 and K11, the proprietary technology and related verification technology related to the pilot manufacturing and verification of K3 and K11, the clinical research approval and phase I clinical research results and data of K3 drug, all intellectual property rights and related information of human monoclonal antibody K3 and K11 Patents and technical secrets After Beijing saisheng Pharmaceutical Co., Ltd has obtained the listing license of K3 and K11 drugs, green bamboo biology has the right of income distribution for a period of ten years from the date when the drugs are listed and sold (calculated from the first invoice) The original announcement is as follows:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.